Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial to Evaluate the Addition of Nivolumab to Neoadjuvant Chemoradiation With FOLFOX for Locally Advanced Rectal Cancer

NCT03921684 is registered in ClinicalTrials.gov with Baruch Brenner as lead sponsor.

NCT NCT03921684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03921684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial to Evaluate the Addition of Nivolumab to Neoadjuvant Chemoradiation With FOLFOX for Locally Advanced Rectal Cancer
Lead sponsor
Baruch Brenner
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 10, 2019
Completion date
October 31, 2029
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer